Sign up now and fund within 24h to get A$10.
Claim It Now

CSL Limited

1 day chart

Get A$10 trading credit to start you off

Sign up and fund a new Stake AUS account and enjoy an extra A$10 trading credit on us.

Sign up and fund a new Stake AUS account and get A$10 bonus trading credit.

T&Cs apply
Claim now
Get A$10 trading credit to start you off

About CSL

CSL Limited (CSL) is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines. CSL's operating model is based around four key value creation activities: early stage research, product translation, manufacturing, and patient access. CSL's commercial and functional areas operate globally.

Buy Australian shares starting with CSL. Invest today with a CHESS-sponsored investing platform!


Health Care






Market Capitalisation


Price-earnings ratio


Dividend yield


High today


Low today


Open price


52-week high


52-week low



What does CSL Limited (CSL) do and how does it make money?

We're talking about the fifth largest biotech company in the world right now. Headquartered in Melbourne, CSL Limited (CSL) is a researcher, developer, manufacturer, marketer, and distributor of biopharmaceutical and allied products. When it comes to protein therapies and influenza vaccines, it is the world's first and second largest company.

This global biotech leader predominantly operates in Australia, the USA, Germany, the United Kingdom, Switzerland and China, and also has a strong presence in the Netherlands, Japan and Hong Kong.

CSL records revenue via two distinct businesses: CSL Behring and Seqirus. 

CSL Behring

CSL Behring’s medicines help to treat people with rare and/or serious immunological, haematological, respiratory, cardiovascular and metabolic diseases. It also conducts early stage research on plasma and non-plasma therapies, excluding influenza.

CSL Behring has markets in more than 100 countries across the Asia Pacific, Europe, Latin America and North America. It commercialises intellectual property to receive licence and royalty income and undertakes the bulk of administrative and corporate functions to support CSL as a whole.

CSL Behring’s revenue makes up more than 80% of CSL’s overall revenue.


Seqirus researches, develops, manufactures and distributes non-plasma biotherapeutic products. It's a leading influenza vaccine provider and a major contributor to the prevention of influenza, globally. It is also a transcontinental partner in pandemic preparedness. 

Utilising both egg-based and cell-based manufacturing technologies, Seqiris offers a broad range of seasonal, pre-pandemic and pandemic influenza vaccines to people all over the world.

With commercial operations in more than 20 countries, Seqirus aims to “lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences”.

Seqirus is also the world’s only supplier of a unique range of products made for the Australian Government, including antivenoms and Q fever vaccine.

What does CSL stand for?

CSL stands for Commonwealth Serum Laboratories. 

CSL was founded in 1916 with the purpose of providing Australians with quick access to 20th century medical advances such as insulin, penicillin, vaccines against influenza, polio and other infectious diseases.

Is CSL a profitable company?

Yes, CSL is a profitable company.

Between FY2012 and FY2021, the company’s revenue grew at a steady compound annual growth rate (CAGR) of 9.5% from A$6.41b to A$14.51b.

The company’s net income also grew at a steady CAGR of 10.01% from A$1.42b to A$3.36b for the same period.

At the end of FY2021, CSL held A$2.76b of free cash flow on its books.

Is CSL a good buy?

CSL has grown its numbers along its top and bottom lines for an entire decade without fail. The company is also a consistent dividend payer. For long-term investors, CSL may be a good stock to buy and hold. 

Other investors may be wary of inflationary pressures, escalating interest rates and the knock-on effects of geopolitical tensions between Russia and Ukraine, and even China and Australia at this time.

Does CSL stock pay dividends?

Yes, CSL has distributed dividends to shareholders twice a year since 2010.

In 2021, CSL paid a dividend of $1.35 in April and another dividend of A$1.59 in September. The total for the year came to $2.94 per share.

In 2022, CSL paid its first dividend of A$1.42 in April. The company paid the final dividend on 5 October 2022, of $1.86.

The company does not offer a dividend reinvestment plan to owners of the stock.

Who owns CSL stock?

The general public holds 73.1% of all CSL stock. Institutions hold 26.8% and individual insiders own 0.1%.

Some institutions with the largest ownership include BlackRock (5.68%), The Vanguard Group (4.26%), BNP Paribas Arbitrage Sa, Asset Management Arm (1.7%), Norges Bank Investment Management (1.43%), WCM Investment Management, LLC (1%), Colonial First State Investments Limited (0.92%), Capital Research and Management Company (0.83%), Commonwealth Superannuation Corporation (0.64%) and Geode Capital Management, LLC (0.53%).

How do I buy CSL stock?

Stake offers a quick and easy way to purchase CSL shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is CHESS sponsored, meaning that when you invest in ASX stocks, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding CSL, sign up today.

Ready to start your investing journey with Stake?

Open an account


Yes, the Stake platform allows you to buy CSL shares and over 12,000 stocks and ETFs across the ASX and Wall St.

One share of CSL Limited is valued at $311.70.

The ticker symbol for CSL Limited is CSL.

To buy CSL stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake AUS
  3. Deposit directly into your Stake wallet and you're ready to invest in CSL

The CSL Limited 52-week high stock price is $311.70.

The CSL Limited 52-week low stock price is $228.65.

As of 21/07/2024 CSL Limited has a market cap of $150.63B.

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in CSL
on Stake

Buy CSL from AU$3 brokerage

Invest in 2,500+ Aussie stocks and ETFs

CHESS-sponsored ASX trades

Get started
Canstar award phone
CSL related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Sanlam Private Wealth Pty Ltd (Australian Financial Services Licence No. 337927) ('Sanlam') and an authorised representative (Authorised Representative No. 1241398) of Airwallex Pty Ltd (Australian Financial Services Licence No. 487221) ('Airwallex'). Stake is not authorised by Airwallex under Airwallex’s AFSL to arrange for clients to be issued with securities as Airwallex is not authorised under its AFSL for this purpose. Stake is not authorised by Sanlam under Sanlam’s AFSL to arrange for clients to be issued with a non-cash payment facility as Sanlam is not authorised under its AFSL for this purpose. Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. Stakeshop Pty Ltd will also run marketing and promotions to you under. For more information about SMSFs, see our SMSF Risks page.The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers  before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.